1. High‐dose transdermal nicotine in Parkinson's disease patients: a randomized, open‐label, blinded‐endpoint evaluation phase 2 study. (23rd October 2017) Authors: Villafane, G.; Thiriez, C.; Audureau, E.; Straczek, C.; Kerschen, P.; Cormier‐Dequaire, F.; Van Der Gucht, A.; Gurruchaga, J.‐M.; Quéré‐Carne, M.; Evangelista, E.; Paul, M.; Defer, G.; Damier, P.; Remy, P.; Itti, E.; Fénelon, G. Journal: European journal of neurology Issue: Volume 25:Number 1(2018) Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A prospective observational post‐marketing study of natalizumab‐treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. (12th June 2013) Authors: Outteryck, O.; Ongagna, J.C.; Brochet, B.; Rumbach, L.; Lebrun‐Frenay, C.; Debouverie, M.; Zéphir, H.; Ouallet, J.C.; Berger, E.; Cohen, M.; Pittion, S.; Laplaud, D.; Wiertlewski, S.; Cabre, P.; Pelletier, J.; Rico, A.; Defer, G.; Derache, N.; Camu, W.; Thouvenot, E. Journal: European journal of neurology Issue: Volume 21:Number 1(2014:Jan.) Page Start: 40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗